<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To explore the treatment of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 7 cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (subtype of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>) were treated in combination of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CsA) with stanozolol </plain></SENT>
<SENT sid="1" pm="."><plain>Duration of treatment with CsA was 5 months-3 years (mean 13 months) </plain></SENT>
<SENT sid="2" pm="."><plain>The results showed that among 7 cases 6 were effective, 1 case no responded to treatment </plain></SENT>
<SENT sid="3" pm="."><plain>3 cases out of 6 effective cases achieved complete remission without transfusion dependence, 1 cases achieved partial remission, 2 cases were improved </plain></SENT>
<SENT sid="4" pm="."><plain>During the investigation signs of <z:hpo ids='HP_0001909'>leukemia</z:hpo> ot other <z:mp ids='MP_0002018'>malignant tumors</z:mp> not were found in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, CsA treatment is effective for part cases of RA, side effects of drugs are tolerable for patients </plain></SENT>
</text></document>